×
About 645 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  234 results

FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed I...
https://doi.org/10.1161/STROKEAHA.121.034191
Stroke Tennenbaum J, Groh M et. al.

Jul 27th, 2021 - Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P) leads to the proliferation of the eosinophilic lineage and thus to a clon...

Novel mechanisms of action contributing to Benralizumab's potent anti-eosinophilic acti...
https://doi.org/10.1183/13993003.04306-2020
The European Respiratory Journal; Dagher R, Kumar V et. al.

Jul 23rd, 2021 - Benralizumab is a humanised, anti-IL-5Rα monoclonal antibody with anti-eosinophilic activity. Lack of fucose (afucosylation) increases its affinity to CD16a and significantly enhances antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cell...

The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kin...
https://doi.org/10.1002/iid3.495
Immunity, Inflammation and Disease; Requena G, Logie J et. al.

Jul 23rd, 2021 - Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real-world data from patients in the United Kingdom. Primary care data from the Clinical Practice Research Datali...

Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomat...
https://doi.org/10.1016/j.clinthera.2021.05.014
Clinical Therapeutics; Pouliquen IJ, Austin D et. al.

Jul 1st, 2021 - Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.|2021|Pouliquen IJ,Austin D,Steinfeld J,Yancey SW,|

Hypereosinophilic syndrome: considerations for the cardiologist.
https://doi.org/10.1136/heartjnl-2020-317202
Heart (British Cardiac Society); Bondue A, Carpentier C et. al.

Jun 27th, 2021 - Eosinophil-mediated endomyocardial damage is a well-known complication in patients with hypereosinophilic syndromes (HES). Although management and survival have improved significantly, some patients continue to develop severe cardiomyopathy as a d...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  8 results

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Apr 24th, 2020 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
https://clinicaltrials.gov/ct2/show/NCT03306043

Jan 13th, 2020 - This is an open-label extension study to Study 200622.In this study subjects from Study 200622 will be continued on 4-weekly dosing with open-label mepolizumab 300 milligram (mg) subcutaneously (SC) for an additional 20 Weeks after completing the ...

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00097370

Jul 7th, 2017 - This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate...

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
https://clinicaltrials.gov/ct2/show/NCT00171912

Feb 23rd, 2017 - Condition Diverse malignancies either associated with or thought to be associated with activated tyrosine kinase enzymes including hypereosinophilic syndrome systemic mastocytosis chronic myelomonocytic leukaemia, dermatofibrosarcoma protuberans a...

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
https://clinicaltrials.gov/ct2/show/NCT00483067

Aug 2nd, 2012 - Before the study begins, patients will have a physical exam, blood tests, and urine tests. Women will have a pregnancy test. A bone marrow sample will be taken. This is done with a large needle. Heart tests and an MRI scan of the brain will be don...

see more →

News  5 results

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CHMP recommends approval of generic imatinib
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

Imatinib Mesylate–Induced Lichenoid Drug Eruption
https://www.mdedge.com/dermatology/article/132728/nonmelanoma-skin-cancer/imatinib-mesylate-induced-lichenoid-drug-eruption/page/0/1

Mar 6th, 2017 - Comment In addition to CML, imatinib has been approved for acute lymphoblastic leukemia, myelodysplastic syndromes, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and G.

Did poor communication lead to her death?
https://www.mdedge.com/obgyn/article/78607/practice-management/did-poor-communication-lead-her-death/page/0/1

Oct 29th, 2013 - Labor progressed slowly. After three attempts at vacuum-assisted delivery, the ObGyn recommended cesarean delivery.

see more →

Patient Education  3 results see all →